Healthcare news on October 16, 2026

1. 0100:27 UTC

   Coverage recordTradingView: “Austco Healthcare Expands Software Reach with $15m RTM Acquisition”

   2 outlets · first: TradingView Acquisition

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by TradingView and smallcaps.com.au.

   • Austco Healthcare
   • RTM

2. 0205:00 UTC

   FDA approves Roche's Enspryng as first at-home shot for thyroid eye disease

   2 outlets · first: roche.com Regulation

   Machine summary Roche announced on 16 October 2026 that the FDA approved Enspryng (satralizumab) for adults with thyroid eye disease, which the company describes as the first and only at-home subcutaneous treatment for the condition. Roche reported that in the Phase III SatraGO-2 trial, proptosis response reached 52.9% with Enspryng versus 23.4% on placebo, while SatraGO-1 did not meet its pre-specified primary endpoint at Week 24. Administration can be performed by the patient or a caregiver after training from a healthcare provider, according to the company.

   1. Roche announced on 16 October 2026 that the FDA approved Enspryng (satralizumab) for adults with thyroid eye disease, describing it as the first and only at-home subcutaneous option for the condition.
   2. Roche describes Enspryng as a first-in-class IL-6 receptor inhibitor; administration can be done by the patient or a caregiver following training from a healthcare provider.
   3. Roche said its Phase III SatraGO-1 study fell short of the primary efficacy endpoint pre-specified at Week 24.
   4. SatraGO-2 produced proptosis response of 52.9% in the Enspryng group versus 23.4% on placebo, per the company's release.
   5. Roche reported a diplopia reduction of 60.7% in the Enspryng group in the SatraGO-2 results cited in the announcement.

   Reported by roche.com and Seeking Alpha.

   • Roche
   • Enspryng (satralizumab)

3. 0300:06 UTC

   Jefferson Hospital opens first breast milk drop-off site in the South Hills

   2 outlets · first: 90.5 WESA Market trends

   Machine summary Allegheny Health Network's Jefferson Hospital opened a Milk Bank Depot in its Healthy Food Center, described as the first donation drop-off site in Pittsburgh's South Hills. According to 90.5 WESA, the Strip District lab of the Mid-Atlantic Mothers' Milk Bank receives collected milk for pasteurization and testing prior to the nonprofit's distribution of it to hospitals throughout Pennsylvania.

   1. According to 90.5 WESA, Jefferson Hospital has opened a Milk Bank Depot that was described as the first such option in the South Hills, forming part of an ongoing partnership that joins Allegheny Health Network with the Mid-Atlantic Mothers' Milk Bank.
   2. Milk collected at the hospital is sent to the milk bank's lab in Pittsburgh's Strip District for testing and pasteurization before distribution to hospitals across Pennsylvania, the report says.
   3. A new freezer chest in Jefferson Hospital's Healthy Food Center was already holding donated breast milk in date-labeled bags at the time of the opening, according to the report.
   4. Characterized as a nonprofit based in Pittsburgh, the Mid-Atlantic Mothers' Milk Bank provides donor milk obtained through ethical sourcing to babies requiring medical care, whether hospitalized or treated as outpatients, across Pennsylvania and West Virginia as well as portions of New Jersey and Maryland.
   5. The report cites donated breast milk as an effective supplement for the treatment of conditions such as neonatal hypoglycemia.

   Reported by 90.5 WESA and Wesa.

   • Neonatal hypoglycemia
   • Mid-Atlantic Mothers' Milk Bank
   • Allegheny Health Network
   • Healthy Food Center
   • Milk Bank Depot
   • Jefferson Hospital

4. 0421:03 UTC

   NIH grant backs MSU work on viral fusion for flu and HIV vaccines

   2 outlets · first: Pharmacy Times Funding

   Machine summary On October 16, 2026, Pharmacy Times reported that Michigan State University researchers had received an NIH grant to examine viral fusion, a mechanism common to influenza and HIV, in the search for new antivirals and broadly protective vaccines. The project is led by chemistry professor David Weliky, PhD. CDC's early numbers, called preliminary, show at least 32 million sicknesses, 390,000 hospital stays, and 24,000 fatalities for the 2025‑2026 flu season; UNAIDS reported 41.0 million HIV‑positive individuals in 2025.

   1. Michigan State University researchers received a National Institutes of Health grant to study viral fusion shared by influenza and HIV, Pharmacy Times reported on October 16, 2026
   2. David Weliky, PhD, a professor at MSU's Department of Chemistry, leads the project.
   3. Preliminary estimates from the CDC about the 2025-2026 flu season suggest a minimum of 32 million cases of illness, 390,000 hospitalizations, plus 24,000 deaths; the agency rated the season moderately severe.
   4. UNAIDS estimates that around 41.0 million individuals across the globe had HIV in 2025; during that same year, 1.2 million new infections occurred and 570,000 people died of AIDS-related illnesses.
   5. About 5.0 million people living with HIV did not know their status, per UNAIDS figures cited in the report

   Reported by Pharmacy Times.

   • National Institutes of Health
   • UNAIDS
   • HIV
   • influenza
   • viral fusion
   • Michigan State University

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.